A
VRDN icon

AJOVista’s Viridian Therapeutics VRDN Stock Holding History

AJOVista’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$201K Buy
+8,817
New +$144K 0.86% 35

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

AJOVista's VRDN Position: Q3 2024 in Review

AJOVista opened a new position in Viridian Therapeutics (VRDN) in Q3 2024: 8,817 shares worth $201K. The stake represents 0.86% of the portfolio and ranks #35 among its holdings.

165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • AJOVista held 8,817 shares of Viridian Therapeutics worth $201K as of Q3 2024.
  • Viridian Therapeutics was a new AJOVista position in Q3 2024.
  • Viridian Therapeutics made up 0.86% of AJOVista's portfolio in Q3 2024, its #35 holding.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.